Red yeast

Red Yeast Rice (Monascus purpureus): A Comprehensive Reference

1. Identity, Nomenclature, and Natural Source

Red yeast rice (RYR) is a Chinese traditional folk medicine produced by the fermentation of cooked rice kernels with a Monascaceae mold, Monascus purpureus. It is a bright reddish-purple fermented rice used as a dietary supplement, and the reddish-purple color derives from the mold Monascus purpureus.

The product is known by numerous names across cultures. In Chinese, it is rendered as 红曲米 (simplified) or 紅麴米 (traditional), pinyin: hóng qū mǐ (literally "red yeast rice"); in Japanese it is known as beni kōji or akakoji; it is also called red fermented rice, red kojic rice, red koji rice, anka, or ang-kak. The proprietary extract Xuezhikang (血脂康) is a well-studied partial extract of RYR. The original Cholestin formulation containing RYR is still available as a food supplement in Asia, New Zealand, and South Africa, while Xuezhikang is sold as a dietary supplement in China; LipoCol Forte, with similar constituents to Xuezhikang, is approved as a drug in Taiwan.

Production and Common Preparations

Red yeast rice is produced by cultivating the mold species Monascus purpureus on rice for 3–6 days at room temperature. The rice grains turn bright red at the core and reddish-purple on the outside. The fully cultured rice is then either sold as the dried grain, or cooked and pasteurized to be sold as a wet paste (known as hongzhao), or dried and pulverized.

Monascus purpureus is traditionally used to make red rice vinegar, Peking duck, and Korean rice wine. It has also been used to color a wide variety of food products, including pickled tofu, red rice vinegar, char siu, Peking duck, and Chinese pastries that require red food coloring. It is also traditionally used in the production of several types of Chinese huangjiu (Shaoxing jiu), Japanese sake, and Korean rice wine, imparting a reddish color to these wines.

In modern commerce, red yeast rice is a traditional Chinese medicine and food supplement popular in East Asian countries such as China, Japan, Korea, and Thailand. Supplement forms include standardized capsules, tablets, and powders.

2. Traditional and Historical Use

Origins and Cultural Context

The use of red yeast rice in China was first documented in the Tang Dynasty in 800 AD. It has been used to make rice wine, as a food preservative for maintaining the color and taste of fish and meat, and for its medicinal properties.

A complete and detailed description of its manufacture is found in the ancient Chinese pharmacopoeia Ben Cao Gang Mu-Dan Shi Bu Yi, published during the Ming Dynasty (1368–1644). In this text, red yeast rice is characterized as mild and useful for improving blood circulation. Red yeast rice is also described in the Chinese pharmacopoeia Ben Cao Gang Mu by Li Shizhen, compiled around 1590. Recommendations in that text were to take it internally to invigorate the body, aid in digestion, and revitalize the blood.

Traditional Indications

RYR has long been used to treat blood circulation stasis, indigestion, diarrhea, and limb weakness in East Asian countries. In traditional Chinese medicine (TCM), red yeast rice is considered mild in nature, slightly sweet, and non-toxic. It is believed to act on the liver, spleen, and large intestine meridians. Red yeast rice was commonly used to treat conditions such as indigestion, diarrhea, fatigue, and limb weakness, and was sometimes recommended as part of the diet for individuals with heart-related ailments.

In TCM, red yeast rice is believed to have the functions of promoting blood circulation, resolving stasis, strengthening the spleen, and promoting digestion. It was often prescribed for people with poor digestion or those who had suffered from blood stasis due to injuries.

Modern Rediscovery

A modern-era use as a dietary supplement developed in the late 1970s after researchers were isolating lovastatin from Aspergillus and monacolins from Monascus, the latter being the same fungus used to make red yeast rice. Chemical analysis soon showed that lovastatin and monacolin K were identical. Lovastatin became the patented prescription drug Mevacor. Monacolin K, a metabolite of Monascus sp., was identified and shown to significantly lower serum cholesterol levels by Japanese scholar Professor Endo in the 1970s.

3. Chemical Composition and Key Constituents

More than 101 chemical constituents have been isolated from RYR, mainly consisting of monacolins, pigments, organic acids, sterols, decalin derivatives, flavonoids, polysaccharides, and other compounds.

Monacolins

RYR contains sugars (25% to 73%, mainly starch), proteins (14% to 31%), water (2% to 7%), fatty acids (1% to 5%), pigments, sterols, and isoflavones. During the fermentation process, the yeast enriches the rice with polyketides with clinically detectable cholesterol-lowering action — the monacolins. Usually, the monacolin concentration in RYR dietary supplements is up to 1.9%. Depending on the conditions of the yeast fermentation and the strain used, several types of monacolins have been identified to date, including compactin and monacolins M, L, J, and X, as well as the subtype monacolin K, which is structurally identical to lovastatin and consequently used as a marker of product purification.

The cholesterol-lowering effects are due to the occurrence of monacolin K, which is often present as a mixture of monacolin K lactone (MK) and monacolin K hydroxy acid (MKA). MK is structurally similar to the cholesterol-lowering medicine lovastatin.

Pigments

Different pigments have been identified in Monascus, such as ankaflavin and monascin (yellow), rubropunctatin and monascorubrin (orange), and rubropunctamine and monascorubramine (purple). There is evidence to indicate that the pigments found in RYR have hypolipidemic, anti-cancer, anti-fatigue, and anti-inflammatory activities, and therefore the presence of pigments may be a critical indicator of extract quality.

Other Bioactive Compounds

Phytochemical investigation of Monascus species has resulted in the isolation and identification of azaphilones (yellow, orange, and red pigments), monacolins, flavonoids, fatty acids, organic acids, dimerumic acid, and γ-aminobutyric acid (GABA). In addition to rice starch, protein, fiber, sterols, and fatty acids, red yeast rice contains numerous active constituents, including monacolin K, dihydromonacolin, and monacolins I through VI.

4. Mechanisms of Action

HMG-CoA Reductase Inhibition

The main cholesterol-lowering mechanism of action of RYR is due to the ability of monacolins to reversibly inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in the cholesterol synthesis pathway, the same enzyme inhibited — in a stronger way — by statins. Researchers have determined that monacolin K inhibits the production of cholesterol by stopping the action of this key enzyme in the liver that is responsible for manufacturing cholesterol. The drug lovastatin (Mevacor®) acts in a similar fashion.

Additional Lipid-Relevant Mechanisms

RYR is known to contain at least nine different statins as well as phytosterols, and thus it decreases both the body's synthesis of cholesterol and its intestinal absorption.

The association of RYR with other bioactive compounds with different mechanisms of action can be functional to an increased cholesterol-lowering effect: RYR, inhibiting HMG-CoA reductase, has often been added to substances reducing lipid intestinal absorption (soluble fibers, glucomannan, plant sterols, probiotics) or enhancing the hepatic uptake of cholesterol and inducing LDL-C excretion by bile metabolism (berberine, soy proteins, artichoke extracts).

Pigment-Mediated Mechanisms

Bioactivity evaluation of azaphilonoid derivatives isolated from RYR indicated that these compounds possess anti-inflammatory activities with dose-dependent relationships for lipopolysaccharide-induced nitric oxide production, and also showed moderate antiproliferative effects against human laryngeal carcinoma (HEp-2) and human colon adenocarcinoma (WiDr) cell lines in vitro.

A statin, monacolin L, and a red pigment, rubropunctatin, from RYR exhibited very strong cancer cell proliferation inhibitory effects in vitro; rubropunctatin was comparable with anticancer drugs cis-platinum and taxol in IC₅₀ values. Monacolin L and rubropunctatin exerted their anticancer activity via telomerase inhibitory effects. These findings are from in vitro studies only and have not been confirmed in human clinical trials.

5. Scientific Evidence by Area of Use

5.1 Dyslipidemia and Cholesterol Reduction

This is the area with the strongest and most consistent body of human clinical evidence for RYR.

Meta-analyses of randomized controlled trials (RCTs):

A systematic review and meta-analysis (covering clinical trials from January 2012 to May 2022, strictly focused on clinical trials examining the association between RYR extract consumption and lipid parameters in humans) identified fourteen double-blinded clinical trials. The interventions lasted 4–24 weeks. RYR extract consumption statistically significantly reduced total cholesterol (mean absolute reduction: 37.43 mg/dL; 95% confidence interval [CI]: −47.08, −27.79) and LDL-C (mean absolute reduction: 35.82 mg/dL; 95% CI: −43.36, −28.29), but not HDL cholesterol, triglycerides, or apolipoproteins A-I and B. The authors concluded that current evidence is insufficient to establish consensus regarding the efficacy and safety of RYR extract supplementation in humans with hypercholesterolemia.

A separate systematic review and meta-analysis of the effectiveness and safety of red yeast rice extract for cardiovascular risk reduction analyzed 20 randomized trials on 6,663 patients. The placebo-subtracted reduction of LDL was 0.68 to 1.44 mmol/L with a pooled estimate of −1.02 mmol/L (95% CI −1.20; −0.83). The effect of RYR on LDL was not statistically different from statin therapy (0.03 mmol/L [−0.36; 0.41]). The design and reporting of adverse events were in most studies insufficient to make a firm judgement on the safety of red yeast rice extract.

Dosages used in clinical trials: The doses of RYR used in clinical trials varied, from 1,200 to 4,800 mg/day and containing from 4.8 to 24 mg of monacolin K.

5.2 Cardiovascular Outcomes: The CCSPS Trial

The most important evidence for hard cardiovascular endpoints derives from a single large Chinese study. The clinical development of Xuezhikang has included large-scale randomized controlled trials, the most notable being the China Coronary Secondary Prevention Study (CCSPS), a multicenter trial involving nearly 5,000 patients with a history of myocardial infarction.

The CCSPS (4,870 patients, follow-up 4 years), a secondary prevention trial using Xuezhikang, a commercial red yeast rice preparation, produced a 46% reduction in nonfatal myocardial infarction and coronary death.

In meta-analyses, RYR extract at 1,200 mg/day reduced nonfatal MI (risk ratio [RR] = 0.42, 95% CI 0.34 to 0.52), revascularization (RR = 0.58, 95% CI 0.48 to 0.71), and sudden death (RR = 0.71, 95% CI 0.53 to 0.94). RYR extract also lowered LDL (weighted mean difference [WMD] = −20.70 mg/dL, 95% CI −24.51 to −16.90), TC (WMD = −26.61 mg/dL, 95% CI −31.65 to −21.58), TG (WMD = −24.69 mg/dL, 95% CI −34.36 to −15.03), and increased HDL levels (WMD = 2.71 mg/dL, 95% CI 1.24 to 4.17). This meta-analysis indicated that RYR extract in MI patients with borderline hypercholesterolemia is associated with improved cardiovascular outcomes and lipid profiles.

Evidence strength note: The CCSPS and its subgroup analyses are highly cited, but the trial was conducted in a single ethnic population (Chinese), used one specific proprietary preparation (Xuezhikang), and the quality of safety reporting was considered insufficient by some reviewers. Results may not be fully generalizable to Western populations or other RYR products.

5.3 Statin-Intolerant Patients

A randomized, controlled trial evaluated the effectiveness and tolerability of red yeast rice and therapeutic lifestyle change in patients who cannot tolerate statin therapy, conducted in a community-based cardiology practice. It enrolled 62 patients with dyslipidemia and history of discontinuation of statin therapy due to myalgias. Patients were randomized to receive red yeast rice 1,800 mg (31 patients) or placebo (31 patients) twice daily for 24 weeks. All patients were concomitantly enrolled in a 12-week therapeutic lifestyle change program. RYR can be effective in patients with statin intolerance or patients who do not achieve goals after single therapy with statins or ezetimibe, though this trial's outcomes were confounded by the lifestyle intervention conducted in parallel.

RYR has been shown to be very well-tolerated by patients at doses of monacolin K up to 10 mg/day. In previously statin-intolerant patients, mild myalgia may be reported; however, data on this is inconsistent, and other analyses suggested good tolerability even in those with statin intolerance.

5.4 Carotid Atherosclerosis

Several studies have demonstrated preventive and therapeutic effects of red yeast rice, a traditional Chinese medicine, on carotid atherosclerosis through the reduction of LDL-C level and other risk factors, though the evidence remains inconsistent. Systematic reviews on this endpoint have been conducted, but the body of evidence is smaller and less robust than that for LDL cholesterol reduction alone.

5.5 Lipid Outcomes: Overview from Larger Evidence Syntheses

An overview of 31 systematic reviews involving 165 randomized trials with 14,987 dyslipidemia participants was conducted to summarize the comparative efficacy and safety of RYR preparations. All the systematic reviews showed a high overall risk of bias. Compared to placebo or other lipid-lowering drugs, RYR preparations showed some regulating action on lipids and glucose metabolism, with fewer side effects. High-quality evidence showed RYR (Zhibituo) lowered total cholesterol and triglyceride levels more than placebo.

The EFSA (European Food Safety Authority) has also assessed health claim applications: The EFSA NDA Panel assessed two health claim applications on monacolin K from RYR and maintenance of normal blood LDL-cholesterol concentrations with a favourable outcome. To obtain the claimed effect, 10 mg of monacolin K from fermented RYR should be consumed daily, in adults in the general population.

5.6 RYR in Combination with Berberine

A meta-analysis of 14 RCTs including data from 3,159 subjects showed that the RYR–berberine association significantly improved plasma LDL-C by −0.61 mmol/L (−23.6 mg/dL; a percentage reduction of 14.7%, p < 0.001), HDL-C by 0.07 mmol/L (p < 0.001), TG by −0.16 mmol/L (p < 0.001), and glucose by −0.14 mmol/L (p = 0.010). The RYR–berberine association tested in association with ezetimibe in statin-intolerant patients reached LDL-C reduction of approximately 35% and TG reduction of approximately 25% compared with baseline, which is similar to what has been reported for moderate-intensity statins.

5.7 Anti-Inflammatory and Oncological Properties

Evidence for anti-inflammatory and anti-cancer effects of RYR is largely preclinical. There is evidence to indicate that the pigments found in RYR have anti-cancer and anti-inflammatory activities in preclinical studies. There are limited reports on mechanisms of anticancer action of red yeast rice in vitro; however, based on existing evidence, red yeast rice or its chemical compositions are considered potentially hopeful anticancer products. These findings have not been replicated in human clinical trials, and no clinical evidence supports RYR for cancer prevention or treatment.

5.8 Metabolic Syndrome and Glucose Metabolism

Animal model data suggest RYR components may have effects beyond lipid lowering. RYR contains monacolin K, a potent inhibitor of HMG-CoA reductase, and its consumption decreases cholesterol and triglyceride levels; the efficacy of RYR constituents was examined using a mouse model of metabolic syndrome and NAFLD. Serum insulin, leptin, liver damage, and macrophage aggregation in visceral fat were lower in RYR groups than in controls, and serum adiponectin levels in the low-monacolin-K RYR group were significantly higher than those in the high-monacolin-K group and control groups. These results are animal-model data only; human clinical trial evidence for RYR in metabolic syndrome, NAFLD, or glycemic control is limited and mixed.

6. Body Systems and Health Areas Associated with RYR

• Cardiovascular system: Cholesterol lowering (strong human evidence), reduction of major cardiovascular events in secondary prevention populations (moderate evidence from CCSPS), carotid plaque stabilization (preliminary evidence).
• Hepatic system: Historically used as a digestive aid; monacolins metabolized hepatically; the liver is both a site of pharmacological action (HMG-CoA reductase) and a potential site of toxicity.
• Musculoskeletal system: Adverse effects on muscle (myopathy, rhabdomyolysis) are a recognized safety concern, mirroring statin-class effects.
• Gastrointestinal system: Historical traditional use for indigestion, diarrhea, and digestive weakness; minor GI side effects observed in clinical trials.
• Immunological / inflammatory system: Pigment constituents show anti-inflammatory properties in vitro; the extent of clinical relevance is not established.
• Oncological: In vitro anti-proliferative activity of specific pigments and monacolins has been reported; no human clinical evidence exists for anti-cancer effects.

7. Dosage Forms and Dosages Reported in Studies

The doses of RYR used in clinical trials were different, varying from 1,200 to 4,800 mg/day and containing from 4.8 to 24 mg of monacolin K.

In the statin-intolerant patient RCT, patients received red yeast rice 1,800 mg twice daily (total 3,600 mg/day) or placebo for 24 weeks.

The CCSPS regimen — which provides the strongest existing evidence for cardiovascular mortality benefit — used 1,200 mg/day Xuezhikang providing 10–12.8 mg total lovastatin.

The EFSA has stated that to obtain the claimed effect of maintaining normal blood LDL-cholesterol concentrations, 10 mg of monacolin K from fermented RYR should be consumed daily.

Product variability is a significant practical limitation. Concerns about the safety of red yeast rice generally relate not to the monacolin content per se, but to batch-to-batch variability in monacolin content and especially the presence of contaminants, particularly citrinin, a nephrotoxic by-product of rice fermentation.

8. Safety Considerations and Drug Interactions

8.1 Regulatory Status

The FDA has ruled that red yeast rice extracts that have more than trace amounts of monacolin K (lovastatin) cannot be sold as a dietary supplement, but some products with detectable levels of lovastatin are commercially available. In 1998, the U.S. FDA initiated action to ban a dietary supplement containing red yeast rice extract, stating that red yeast rice products containing monacolin K are identical to a prescription drug and thus subject to regulation as a drug.

In the European Union: the European Commission prohibited RYR supplements with a maximum serving exceeding 3 mg of total monacolins per day, due to safety concerns linked to the use of statins.

8.2 Myopathy and Rhabdomyolysis

Adverse effects associated with red yeast rice that are repeatedly reported include symptomatic myopathy, gastrointestinal symptoms, and elevated levels of hepatic enzymes indicative of liver injury. The majority of adverse effects reported for red yeast rice are also commonly associated with statin drugs.

The EFSA NDA Panel reiterates that exposure to monacolin K from RYR at intake levels as low as 3 mg/day could lead to severe adverse effects on the musculoskeletal system, including rhabdomyolysis, and on the liver.

Although RYR products have been demonstrated to be well tolerated in prospective trials, consumption has been associated with occurrence of myopathy, rhabdomyolysis, or hepatitis in several case reports.

8.3 Hepatotoxicity

Red yeast rice use has been associated with very rare instances of acute, clinically apparent liver injury. In prospective controlled trials, red yeast rice extract formulations have not been associated with serum enzyme elevations or clinically apparent liver injury at reported rates that exceed control groups.

8.4 Citrinin Contamination

RYR is known as the food product with the highest incidence of severe contamination with the nephrotoxic mycotoxin citrinin, potentially produced by M. purpureus. Initially, the limits for citrinin present in RYR supplements were set at 2,000 µg/kg. However, in 2019, the European Commission lowered the maximum tolerated levels of citrinin in RYR-containing dietary supplements to 100 µg/kg due to safety concerns.

The EFSA CONTAM Panel assessed citrinin as a nephrotoxic mycotoxin that can be produced by some strains of Monascus purpureus. The maximum level of citrinin (100 µg/kg) in food supplements based on rice fermented with the red yeast Monascus purpureus is regulated by Regulation (EU) 2023/915.

8.5 Product Variability

Red yeast rice dietary supplements are largely sold in Western countries for their cholesterol-lowering effect due to monacolins, mainly monacolin K; however, among 31 RYR dietary supplements analyzed, significant variability in monacolin content was found. The safety profile of red yeast rice is mainly based on case reports, and assessment is complicated by self-medication and varying product composition. Continuous monitoring and further long-term trials are indispensable.

8.6 Drug Interactions

Strong CYP3A4 inhibitors can increase the risk of myopathy by increasing the drug plasma concentration and consequently the inhibition of HMG-CoA reductase during lovastatin or red yeast rice therapy. These inhibitors include cyclosporin, itraconazole, clarithromycin, verapamil, aprepitant, amiodarone, as well as HIV protease inhibitors such as ritonavir and other cholesterol-lowering agents such as fibrates. Grapefruit juice, if consumed in large amounts, may also significantly increase the inhibitory activity of lovastatin on HMG-CoA reductase.

Combining red yeast rice with prescription statins increases all statin-related risks and should be avoided. Fibrates (e.g., gemfibrozil) potentiate myopathy risk through pharmacodynamic synergy with lovastatin. There is potential for altered warfarin pharmacokinetics; INR monitoring is advised.

St. John's wort taken with red yeast rice might lessen how well the red yeast rice works, as this herb induces CYP3A4, the enzyme responsible for the metabolism of monacolin K.

8.7 Populations of Concern

Red yeast rice is contraindicated in pregnancy, breastfeeding, active liver disease, and in individuals with previous statin-induced myopathy; it should never be combined with prescription statins. In patients receiving red yeast rice, the potential nephrotoxicity by citrinin can lead to renal failure.

References

• Zhu B, et al. "Red Yeast Rice: A Systematic Review of the Traditional Uses, Chemistry, Pharmacology, and Quality Control of an Important Chinese Folk Medicine." Frontiers in Pharmacology 2019;10:1449. PMC6901015
• National Center for Complementary and Integrative Health (NCCIH/NIH). "Red Yeast Rice." U.S. Department of Health and Human Services.
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. "Red Yeast Rice." NCBI Bookshelf, National Library of Medicine.
• Trogkanis E, et al. "Safety and Efficacy of the Consumption of the Nutraceutical 'Red Yeast Rice Extract' for the Reduction of Hypercholesterolemia in Humans: A Systematic Review and Meta-Analysis." Nutrients 2024;16(10):1453. PMC11124448
• Dujovne CA, et al. "Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain — A systematic review and meta-analysis." Atherosclerosis 2015;240(2):415–423.
• Li X, et al. "Efficacy of red yeast rice extract on myocardial infarction patients with borderline hypercholesterolemia: A meta-analysis of randomized controlled trials." Scientific Reports 2020. PMC7026145
• Cicero AFG, et al. "Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar." Journal of the American College of Cardiology 2021;77(5):619–628.
• Zhao Y, et al. "Red yeast rice preparations for dyslipidemia: An overview of systematic reviews and network meta-analysis." Journal of Functional Foods 2023;104:105516.
• Wang X, et al. "Effectiveness of red yeast rice on carotid atherosclerosis: A systematic review and meta-analysis." Frontiers in Pharmacology 2022;13:937809. PMC9478999
• Becker DJ, et al. "Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial." Annals of Internal Medicine 2009;150(12):830–839.
• Göbel RJ, Rüegg E. "Mini-review: medication safety of red yeast rice products." Phytotherapy Research 2019. PMC6500871
• Huang CF, et al. "Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin." Evidence-Based Complementary and Alternative Medicine 2012. PMC3513969
• Quality Control and Safety Assessment of Online-Purchased Food Supplements Containing Red Yeast Rice (RYR). Foods 2024. PMC11202976
• EFSA NDA Panel. "Scientific Opinion on additional scientific data related to the safety of monacolins from red yeast rice." EFSA Journal 2025. PMC11868785
• Banach M, et al. "Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel." Pharmacological Research 2022;183:106370.
• Hachem R, et al. "Comparative Chemical Profiling and Monacolins Quantification in Red Yeast Rice Dietary Supplements by ¹H-NMR and UHPLC-DAD-MS." Molecules 2020;25(2):317. PMC7024183
• Fujimoto M, et al. "Study of the Effects of Monacolin K and Other Constituents of Red Yeast Rice on Obesity, Insulin-Resistance, Hyperlipidemia, and Nonalcoholic Steatohepatitis Using a Mouse Model of Metabolic Syndrome." Evidence-Based Complementary and Alternative Medicine 2012. PMC3541547
• Hsu YW, et al. "New Anti-Inflammatory and Anti-Proliferative Constituents from Fermented Red Mold Rice Monascus purpureus NTU 568." Molecules 2010;15:7815–7827. PMC6259223
• Li X, et al. "Telomerase Inhibitory Effects of Red Pigment Rubropunctatin and Statin Monacolin L Isolated from Red Yeast Rice." Evidence-Based Complementary and Alternative Medicine 2017. PMC5448003
• Reiner Ž. "Red Yeast Rice Preparations: Are They Suitable Substitutions for Statins?" The American Journal of Medicine 2018;131(1):21–24.
• Rashidpour M, et al. "Evaluation the effects of red yeast rice in combination with statin on lipid profile and inflammatory indices; a randomized clinical trial." BMC Nutrition 2022;8:132. PMC9700919
• Wikipedia. "Xuezhikang." (summary of CCSPS study and traditional use context).
• Heber D, et al. "Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement." American Journal of Clinical Nutrition 1999;69(2):231–236.